Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeAgeTrial IDs
Phase III, Phase IIBiomarker/Laboratory analysis, Treatment18 and overRTOG 0848
NCI-2011-01987, CDR0000659092, NCT01013649

Trial Description

Summary

This randomized phase II-R/III trial studies gemcitabine hydrochloride with or without erlotinib hydrochloride followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil in treating patients with pancreatic cancer that was removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride, capecitabine, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells. Giving chemotherapy together with or without erlotinib hydrochloride and/or radiation therapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether chemotherapy is more effective when given with or without erlotinib hydrochloride and/or radiation therapy in treating pancreatic cancer.

Further Study Information

PRIMARY OBJECTIVES:

I. To determine whether the addition of erlotinib (erlotinib hydrochloride) to gemcitabine (gemcitabine hydrochloride) adjuvant chemotherapy shows a signal for improved survival as compared to gemcitabine alone following R0 or R1 resection of head of pancreas adenocarcinoma (including adenocarcinoma of the head, neck, and uncinate process). (Phase II-R)

II. To determine whether the use of concurrent fluoropyrimidine and radiotherapy following adjuvant gemcitabine hydrochloride-based chemotherapy further enhances survival for such patients who are without evidence of progressive disease after 5 cycles of gemcitabine based chemotherapy. (Phase III)

SECONDARY OBJECTIVES:

I. To evaluate disease-free survival of adjuvant chemotherapy followed by radiotherapy and concurrent fluoropyrimidine for patients with resected head of pancreas adenocarcinoma who are disease free after 5 cycles of adjuvant chemotherapy.

II. To evaluate disease-free survival of standard adjuvant gemcitabine chemotherapy with and without erlotinib for patients with resected head of pancreas adenocarcinoma.

III. To evaluate adverse events with and without erlotinib for patients with resected head of pancreas adenocarcinoma.

IV. To evaluate adverse events of adjuvant chemotherapy with or without radiation therapy and concurrent fluoropyrimidine for patients with resected head of pancreas adenocarcinoma who are disease free after adjuvant chemotherapy.

V. To evaluate preoperative cross-sectional imaging of the primary head of pancreas adenocarcinoma in order to determine the frequency with which objective criteria of resectability are present.

VI. To determine if patients reporting low baseline fatigue, as measured by the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue, predicts survival and to explore correlations between baseline fatigue, as measured by Patient-Reported Outcomes Measurement Information System (PROMIS), and survival.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 5 courses in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive gemcitabine hydrochloride as in arm I and erlotinib hydrochloride orally (PO) once daily on days 1-28. Treatment repeats every 28 days for 5 courses in the absence of disease progression or unacceptable toxicity. (NOTE: Phase II-R erlotinib hydrochloride randomization completed, Arm 2 closed to accrual effective 2/19/2014)

Patients with no disease progression after treatment in arm I or II are then stratified according to their first randomization treatment arm (arm I vs arm II) and randomized to 1 of 2 additional treatment arms (arm III or IV).

ARM III: Patients receive 1 course of the same treatment that they receive in arm I or II.

ARM IV: Patients receive 1 course of the same treatment that they receive in arm I or II. Beginning within 7-21 days after completion of chemotherapy, patients undergo radiotherapy (3-dimensional conformal radiotherapy or intensity-modulated radiotherapy) 5 days per week for 5.5 weeks (28 fractions). During radiotherapy, patients receive either capecitabine PO twice daily (BID) 5 days per week or fluorouracil IV continuously for 5.5 weeks or until radiotherapy is completed.

After completion of study treatment, patients are followed up periodically.

Eligibility Criteria

Inclusion Criteria:

Serum total bilirubin =< twice the institutional upper limit of normal (ULN) within 21 days of registration on study

Platelets >= 100,000/mm^3

Hemoglobin (Hgb) >= 8.0 g/dL (transfusion or other intervention to achieve Hgb >= 8.0 g/dl is acceptable)

Creatinine levels =< twice the institutional upper limit of normal within 21 days of registration on study

Serum glutamic oxaloacetic transaminase (SGOT) must be =< 2.5 x institutional ULN within 21 days of registration on study

Patients will be staged according to the 6th edition American Joint Committee on Cancer (AJCC) staging system with pathologic stage T1-3, N0-1, M-0 being eligible

Complete history and physical examination including weight and Zubrod status within 31 days of study entry

Negative serum pregnancy test for women of childbearing potential within 14 days of study registration

Consultation, agreement, and documentation in the patient’s chart by a radiation oncologist that patient is suitable to receive radiotherapy per this protocol

Signed study-specific informed consent

Zubrod performance status 0 or 1

Before starting therapy the patient should be able to maintain adequate oral nutrition of >= 1500 calories estimated caloric intake per day and be free of significant nausea and vomiting

Absolute neutrophil count (ANC) >= 1,500/mm^3

Women of childbearing potential and male participants must practice adequate contraception

Interval between definitive tumor-related surgery and 1st step registration between 21-70 days

Histologic proof of primary head of pancreas invasive adenocarcinoma managed with a potentially curative resection (i.e., removal of all gross tumor) involving a classic pancreaticoduodenectomy (Whipple) or a pylorus preserving pancreaticoduodenectomy; patients with invasive adenocarcinoma that also contains a component of intraductal papillary mucinous neoplasm (IPMN) are eligible

The operating surgeon must document in the operative note that a complete gross excision of the primary tumor was achieved; the pathology report must include documentation of the margin status and the size of the tumor; the pathology report must also include the status of the three major margins—bile duct, pancreatic parenchyma, and retroperitoneal (uncinate)

Post resection serum cancer antigen (CA)19-9 =< 180 units/mL within 21 days of registration on study

Abdominal/pelvic computed tomography (CT) scan with contrast is preferred; abdominal CT alone is acceptable only if insurance restrictions are experienced; chest CT/x-ray (CT of chest preferred) within 31 days of registration on study; patients allergic to intravenous (IV) contrast can have magnetic resonance imaging (MRI) of the abdomen/pelvis instead

Patients with active human immunodeficiency virus (HIV) infection are eligible if their cluster of differentiation (CD)4 count is > 499/cu mm and their viral load is < 50 copies/ml; use of highly active antiretroviral treatment (HAART) is allowed

Exclusion Criteria:

Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields

Pregnant or lactating women

If surgical margin status cannot be determined after consultation with the operating surgeon and the institutional pathologist, the patient will be ineligible

Patients managed with a total pancreatectomy, a distal pancreatectomy, or central pancreatectomy

Prior systemic chemotherapy for pancreas cancer; note that prior chemotherapy for a different cancer is allowable

Previous history of invasive malignancy (except non-melanoma skin cancer) unless the patient has been disease free for at least 2 years prior to study entry (patients with a previous history of carcinoma in situ are eligible)

Patients with non-adenocarcinomas, adenosquamous carcinomas, islet cell (neuroendocrine) tumors, cystadenomas, cystadenocarcinomas, carcinoid tumors, duodenal carcinomas, distal bile duct, and ampullary carcinomas; patients with tumors that are largely IPMN with a minimal or minor component of invasive carcinoma are not eligible; patients with acinar carcinomas are not eligible; patients with IPMN’s that contain some secondary (minor) foci of adenocarcinoma are also not eligible

Women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception

Severe, active co-morbidity, defined as follows:

Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months

Transmural myocardial infarction within the 3 months of study registration

Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration

Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration

Trial Contact Information

Trial Lead Organizations / Sponsors / Collaborators

National Cancer Institute

  • National Cancer Institute
Ross Allen Abrams, Principal Investigator

Trial Sites

U.S.A.

California
Auburn

Sutter Cancer Centers Radiation Oncology Services-Auburn

Christopher Uwe Jones
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Burbank

Providence Saint Joseph Medical Center/Disney Family Cancer Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Burlingame

Mills - Peninsula Hospitals

Christopher Uwe Jones
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Cameron Park

Sutter Cancer Centers Radiation Oncology Services-Cameron Park

Christopher Uwe Jones
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Fresno

California Cancer Center - North Fresno

Uma G. Swamy
Ph: 559-447-4050

Uma G. Swamy
Principal Investigator

Fresno Cancer Center

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Greenbrae

Marin General Hospital

Lloyd T. Miyawaki
Ph: 415-925-7325

Lloyd T. Miyawaki
Principal Investigator

La Jolla

UC San Diego Moores Cancer Center

Ross Allen Abrams
Ph: 312-942-5498

Ross Allen Abrams
Principal Investigator

Los Angeles

Cedars-Sinai Medical Center

Nicholas Naumann Nissen
Ph: 310-423-8965

Nicholas Naumann Nissen
Principal Investigator

Kaiser Permanente Los Angeles Medical Center

Michael Raymond Girvigian
Ph: 626-564-3455

Michael Raymond Girvigian
Principal Investigator

Los Angeles County-USC Medical Center

Syma Iqbal
Ph: 323-865-0451

Syma Iqbal
Principal Investigator

USC / Norris Comprehensive Cancer Center

Syma Iqbal
Ph: 323-865-0451

Syma Iqbal
Principal Investigator

Modesto

Memorial Medical Center

Christopher Uwe Jones
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Oakland

Alta Bates Summit Medical Center - Summit Campus

James Henry Feusner
Ph: 510-450-7600

James Henry Feusner
Principal Investigator

Bay Area Tumor Institute

James Henry Feusner
Ph: 510-450-7600

James Henry Feusner
Principal Investigator

Kaiser Permanente Oakland-Broadway

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Orange

UC Irvine Health/Chao Family Comprehensive Cancer Center

Tara Elisabeth Seery
Ph: 877-827-8839
Email: ucstudy@uci.edu

Tara Elisabeth Seery
Principal Investigator

Rancho Cordova

Kaiser Permanente-Rancho Cordova Cancer Center

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Rohnert Park

Rohnert Park Cancer Center

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Roseville

Sutter Cancer Centers Radiation Oncology Services-Roseville

Christopher Uwe Jones
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

The Permanente Medical Group-Roseville Radiation Oncology

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Sacramento

South Sacramento Cancer Center

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Sutter General Hospital

Christopher Uwe Jones
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Saint Helena

Saint Helena Hospital

David John Tate
Ph: 707-967-3698

David John Tate
Principal Investigator

San Francisco

California Pacific Medical Center-Pacific Campus

Christopher Uwe Jones
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Santa Clara

Kaiser Permanente Medical Center - Santa Clara

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

South San Francisco

Kaiser Permanente Cancer Treatment Center

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Vacaville

Sutter Cancer Centers Radiation Oncology Services-Vacaville

Christopher Uwe Jones
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Vallejo

Sutter Solano Medical Center/Cancer Center

Christopher Uwe Jones
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Colorado
Aurora

Rocky Mountain Cancer Centers-Aurora

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Boulder

Rocky Mountain Cancer Centers-Boulder

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Denver

Porter Adventist Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Englewood

Swedish Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Greeley

North Colorado Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Littleton

Rocky Mountain Cancer Centers-Littleton

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Longmont

Longmont United Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Loveland

McKee Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Parker

Parker Adventist Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Thornton

Rocky Mountain Cancer Centers-Thornton

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Wheat Ridge

Exempla Lutheran Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Connecticut
Bridgeport

Saint Vincent's Medical Center

Christine Van Cott
Ph: 203-576-6329
Email: twhite@stvincents.org

Christine Van Cott
Principal Investigator

Hartford

Hartford Hospital

Andrew L. Salner
Ph: 860-545-5363

Andrew L. Salner
Principal Investigator

New Britain

The Hospital of Central Connecticut

Neal B. Goldberg
Ph: 860-224-5660

Neal B. Goldberg
Principal Investigator

Delaware
Newark

Christiana Care Health System-Christiana Hospital

Adam Raben
Ph: 302-733-6227

Adam Raben
Principal Investigator

Florida
Deerfield Beach

University of Miami Sylvester Comprehensive Cancer Center at Deerfield Beach

Lorraine Portelance
Ph: 866-574-5124
Email: Sylvester@emergingmed.com

Lorraine Portelance
Principal Investigator

Miami

Jackson Memorial Hospital-Holtz Children's Hospital

Lorraine Portelance
Ph: 866-574-5124
Email: Sylvester@emergingmed.com

Lorraine Portelance
Principal Investigator

University of Miami Miller School of Medicine-Sylvester Cancer Center

Lorraine Portelance
Ph: 866-574-5124
Email: Sylvester@emergingmed.com

Lorraine Portelance
Principal Investigator

Miami Beach

Mount Sinai Medical Center

Michael A. Schwartz
Ph: 305-674-2625
Email: info@msccop.com

Michael A. Schwartz
Principal Investigator

Orlando

UF Cancer Center at Orlando Health

Daniel Joseph Buchholz
Ph: 321-841-7246
Email: CancerClinicalTrials@orlandohealth.com

Daniel Joseph Buchholz
Principal Investigator

Georgia
Atlanta

Emory University Hospital Midtown

Bassel F. El-Rayes
Ph: 404-778-1868

Bassel F. El-Rayes
Principal Investigator

Emory University/Winship Cancer Institute

Bassel F. El-Rayes
Ph: 404-778-1868

Bassel F. El-Rayes
Principal Investigator

Saint Joseph's Hospital of Atlanta

Bassel F. El-Rayes
Ph: 404-778-1868

Bassel F. El-Rayes
Principal Investigator

Gainesville

Northeast Georgia Medical Center

Frank Greer Lake
Ph: 770-219-8800
Email: cancerpatient.navigator@nghs.com

Frank Greer Lake
Principal Investigator

Savannah

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler

John A. Pablo
Ph: 800-622-6877

John A. Pablo
Principal Investigator

Memorial University Medical Center

Aaron Watson Pederson
Ph: 912-350-8568

Aaron Watson Pederson
Principal Investigator

Hawaii
Honolulu

Queen's Medical Center

Paul Arthur DeMare
Ph: 808-545-8548

Paul Arthur DeMare
Principal Investigator

The Cancer Center of Hawaii-Liliha

Paul Arthur DeMare
Ph: 808-545-8548

Paul Arthur DeMare
Principal Investigator

University of Hawaii Cancer Center

Paul Arthur DeMare
Ph: 808-545-8548

Paul Arthur DeMare
Principal Investigator

Idaho
Boise

Saint Luke's Mountain States Tumor Institute

Stephen C. Smith
Ph: 888-823-5923
Email: ctsucontact@westat.com

Stephen C. Smith
Principal Investigator

Fruitland

Saint Luke's Mountain States Tumor Institute - Fruitland

Stephen C. Smith
Ph: 888-823-5923
Email: ctsucontact@westat.com

Stephen C. Smith
Principal Investigator

Meridian

Saint Luke's Mountain States Tumor Institute - Meridian

Stephen C. Smith
Ph: 888-823-5923
Email: ctsucontact@westat.com

Stephen C. Smith
Principal Investigator

Nampa

Saint Luke's Mountain States Tumor Institute - Nampa

Stephen C. Smith
Ph: 888-823-5923
Email: ctsucontact@westat.com

Stephen C. Smith
Principal Investigator

Twin Falls

Saint Luke's Mountain States Tumor Institute-Twin Falls

Stephen C. Smith
Ph: 888-823-5923
Email: ctsucontact@westat.com

Stephen C. Smith
Principal Investigator

Illinois
Arlington Heights

Northwest Community Hospital

Stephen Schaeffer Nigh
Ph: 847-618-4968

Stephen Schaeffer Nigh
Principal Investigator

Chicago

John H Stroger Jr Hospital of Cook County

Thomas E. Lad
Ph: 312-864-6000

Thomas E. Lad
Principal Investigator

Northwestern University

John Patrick Hayes
Ph: 312-695-1301
Email: cancer@northwestern.edu

John Patrick Hayes
Principal Investigator

Rush University Medical Center

Ross Allen Abrams
Ph: 312-942-5498
Email: clinical_trials@rush.edu

Ross Allen Abrams
Principal Investigator

University of Chicago Comprehensive Cancer Center

Stanley Lawrence Liauw
Ph: 773-834-7424

Stanley Lawrence Liauw
Principal Investigator

University of Illinois

Neeta Kiran Venepalli
Ph: 312-355-3046

Neeta Kiran Venepalli
Principal Investigator

Decatur

Decatur Memorial Hospital

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Harvey

Ingalls Memorial Hospital

Sulochana D. Yalavarthi
Ph: 708-915-4673
Email: clinicaltrials@ingalls.org

Sulochana D. Yalavarthi
Principal Investigator

Maywood

Loyola University Medical Center

William Small
Ph: 708-226-4357

William Small
Principal Investigator

Naperville

Edward Hospital/Cancer Center

Alexander Hantel
Ph: 630-646-6075

Alexander Hantel
Principal Investigator

Pekin

Pekin Cancer Treatment Center

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Peoria

Methodist Medical Center of Illinois

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

OSF Saint Francis Medical Center

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

OSF Saint Francis Medical Center Radiation Oncology Service at the Central Illinois Comprehensive CC

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Peru

Valley Radiation Oncology

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Plainfield

Edward Hospital/Cancer Center?Plainfield

Alexander Hantel
Ph: 630-646-6075

Alexander Hantel
Principal Investigator

Springfield

Memorial Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Saint John's Hospital

Laurent Brard
Ph: 217-525-5666
Email: diana.weyhenmeyer@st-johns.org

Laurent Brard
Principal Investigator

Urbana

Carle Cancer Center

Kalika Prasad Sarma
Ph: 800-446-5532

Kalika Prasad Sarma
Principal Investigator

Warrenville

Cadence Cancer Center in Warrenville

Christopher M. George
Ph: 630-208-4563
Email: kevin.tomczyk@delnor.com

Christopher M. George
Principal Investigator

Indiana
Elkhart

Michiana Hematology Oncology PC-Elkhart

Robin T. Zon
Ph: 574-234-5123

Robin T. Zon
Principal Investigator

Fort Wayne

Parkview Hospital Randallia

Brian K. Chang
Ph: 260-373-8888
Email: parkviewresearch@parkview.com

Brian K. Chang
Principal Investigator

Radiation Oncology Associates PC

Brian K. Chang
Ph: 260-373-8888
Email: parkviewresearch@parkview.com

Brian K. Chang
Principal Investigator

Mishawaka

Michiana Hematology Oncology PC-Mishawaka

Robin T. Zon
Ph: 574-234-5123

Robin T. Zon
Principal Investigator

South Bend

Memorial Hospital of South Bend

David Alan Hornback
Ph: 800-284-7370

David Alan Hornback
Principal Investigator

Northern Indiana Cancer Research Consortium CCOP

Robin T. Zon
Ph: 574-234-5123

Robin T. Zon
Principal Investigator

Iowa
Ames

McFarland Clinic PC-William R Bliss Cancer Center

Joseph James Merchant
Ph: 515-239-2621

Joseph James Merchant
Principal Investigator

Clive

Mercy Cancer Center-West Lakes

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Des Moines

Iowa Methodist Medical Center

Robert J. Behrens
Ph: 515-282-2921

Robert J. Behrens
Principal Investigator

Medical Oncology and Hematology Associates-Laurel

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Mercy Medical Center - Des Moines

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Sioux City

Siouxland Regional Cancer Center

Donald B. Wender
Ph: 712-252-0088

Donald B. Wender
Principal Investigator

Kansas
Topeka

Stormont-Vail Regional Health Center

David E. Einspahr
Ph: 785-270-4963

David E. Einspahr
Principal Investigator

Wichita

Via Christi Regional Medical Center

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Kentucky
Lexington

Baptist Health Lexington

Firas B. Badin
Ph: 859-260-6425

Firas B. Badin
Principal Investigator

University of Kentucky/Markey Cancer Center

Mahesh Ravindra Kudrimoti
Ph: 859-257-3379

Mahesh Ravindra Kudrimoti
Principal Investigator

Louisiana
New Orleans

Ochsner Medical Center Jefferson

Roland B. Hawkins
Ph: 888-562-4763

Roland B. Hawkins
Principal Investigator

Tulane University Health Sciences Center

William Russell Robinson
Ph: 504-988-6121

William Russell Robinson
Principal Investigator

Maryland
Baltimore

Saint Agnes Hospital

Richard S. Hudes
Ph: 410-368-2910

Richard S. Hudes
Principal Investigator

Sinai Hospital of Baltimore

Mayer Gorbaty
Ph: 410-601-6120
Email: pridgely@lifebridgehealth.org

Mayer Gorbaty
Principal Investigator

University of Maryland/Greenebaum Cancer Center

William Frank Regine
Ph: 800-888-8823

William Frank Regine
Principal Investigator

Salisbury

Peninsula Regional Medical Center

John Romeo Mansueti
Ph: 866-922-6237

John Romeo Mansueti
Principal Investigator

Massachusetts
Boston

Boston Medical Center

Lisa A. Kachnic
Ph: 617-638-8265

Lisa A. Kachnic
Principal Investigator

Burlington

Lahey Hospital and Medical Center

Keith Ellis Stuart
Ph: 781-744-8027

Keith Ellis Stuart
Principal Investigator

Fall River

Saint Anne's Hospital

Raymond L. Dugal
Ph: 877-726-5130

Raymond L. Dugal
Principal Investigator

Springfield

Baystate Medical Center

Seth A. Kaufman
Ph: 413-794-9338

Seth A. Kaufman
Principal Investigator

Michigan
Adrian

Hickman Cancer Center

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

Ann Arbor

University of Michigan Comprehensive Cancer Center

Ross Allen Abrams
Ph: 312-942-5498

Ross Allen Abrams
Principal Investigator

Clinton Township

Henry Ford Macomb Hospital

Eleanor M. Walker
Ph: 313-916-1784

Eleanor M. Walker
Principal Investigator

Detroit

Henry Ford Hospital

Eleanor M. Walker
Ph: 313-916-1784

Eleanor M. Walker
Principal Investigator

Wayne State University/Karmanos Cancer Institute

Peter A. Paximadis
Ph: 313-576-9363

Peter A. Paximadis
Principal Investigator

Farmington Hills

Weisberg Cancer Treatment Center

Peter A. Paximadis
Ph: 313-576-9363

Peter A. Paximadis
Principal Investigator

Kalamazoo

West Michigan Cancer Center

Raymond Sterling Lord
Ph: 269-373-7458

Raymond Sterling Lord
Principal Investigator

Royal Oak

William Beaumont Hospital-Royal Oak

Laura M. Nadeau
Ph: 248-551-7695

Laura M. Nadeau
Principal Investigator

Trenton

Downriver Center for Oncology

Eleanor M. Walker
Ph: 313-916-1784

Eleanor M. Walker
Principal Investigator

Troy

William Beaumont Hospital - Troy

Laura M. Nadeau
Ph: 248-551-7695

Laura M. Nadeau
Principal Investigator

West Bloomfield

Henry Ford Medical Center - West Bloomfield

Eleanor M. Walker
Ph: 313-916-1784

Eleanor M. Walker
Principal Investigator

Minnesota
Fridley

Unity Hospital

Paul W. Sperduto
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Paul W. Sperduto
Principal Investigator

Maplewood

Minnesota Oncology Hematology PA-Maplewood

Paul W. Sperduto
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Paul W. Sperduto
Principal Investigator

Minneapolis

Abbott-Northwestern Hospital

Paul W. Sperduto
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Paul W. Sperduto
Principal Investigator

Robbinsdale

North Memorial Medical Health Center

Paul W. Sperduto
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Paul W. Sperduto
Principal Investigator

Saint Paul

Regions Hospital

Paul W. Sperduto
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Paul W. Sperduto
Principal Investigator

United Hospital

Paul W. Sperduto
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Paul W. Sperduto
Principal Investigator

Missouri
Cape Girardeau

Southeast Cancer Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Rolla

Phelps County Regional Medical Center

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Saint Louis

Barnes-Jewish West County Hospital

Jeffrey Robert Olsen
Ph: 800-600-3606
Email: info@siteman.wustl.edu

Jeffrey Robert Olsen
Principal Investigator

Missouri Baptist Medical Center

Alan P. Lyss
Ph: 800-392-0936

Alan P. Lyss
Principal Investigator

Washington University School of Medicine

Jeffrey Robert Olsen
Ph: 800-600-3606
Email: info@siteman.wustl.edu

Jeffrey Robert Olsen
Principal Investigator

Saint Peters

Siteman Cancer Center - Saint Peters

Jeffrey Robert Olsen
Ph: 800-600-3606
Email: info@siteman.wustl.edu

Jeffrey Robert Olsen
Principal Investigator

Springfield

CoxHealth South Hospital

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Mercy Hospital Springfield

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Nebraska
Grand Island

CHI Health Saint Francis

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Kearney

CHI Health Good Samaritan

Fishel Zev Liberman
Ph: 308-865-7963

Fishel Zev Liberman
Principal Investigator

Omaha

Alegent Health Bergan Mercy Medical Center

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Nebraska Methodist Hospital

Tien-Shew William Huang
Ph: 402-354-5144

Tien-Shew William Huang
Principal Investigator

University of Nebraska Medical Center

Chi Lin
Ph: 402-559-8555
Email: llarson@unmc.edu

Chi Lin
Principal Investigator

Nevada
Henderson

Comprehensive Cancer Centers of Nevada - Henderson

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Las Vegas

Comprehensive Cancer Centers of Nevada

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Comprehensive Cancer Centers of Nevada - Central Valley

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Comprehensive Cancer Centers of Nevada - Northwest

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Comprehensive Cancer Centers of Nevada-Summerlin

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Nevada Cancer Research Foundation CCOP

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Radiation Oncology Centers of Nevada Central

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Reno

Renown Regional Medical Center

Michael Chandler Hardacre
Ph: 775-982-4400

Michael Chandler Hardacre
Principal Investigator

New Jersey
Basking Ridge

Memorial Sloan Kettering Cancer Center at Basking Ridge

Karyn Aalami Goodman
Ph: 212-639-7202

Karyn Aalami Goodman
Principal Investigator

Camden

Cooper Hospital University Medical Center

Ashish Bharat Patel
Ph: 856-325-6757

Ashish Bharat Patel
Principal Investigator

Livingston

Saint Barnabas Medical Center

Delia Radovich
Ph: 973-322-2470

Delia Radovich
Principal Investigator

Mount Holly

Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County

Lemuel S. Ariaratnam
Ph: 888-847-8823

Lemuel S. Ariaratnam
Principal Investigator

Newark

Newark Beth Israel Medical Center

Charles S. Cathcart
Ph: 973-926-7230

Charles S. Cathcart
Principal Investigator

Ridgewood

Valley Hospital

Thomas J. Rakowski
Ph: 201-634-5792

Thomas J. Rakowski
Principal Investigator

Sparta

Sparta Cancer Treatment Center

Adam Craig Berger
Ph: 215-955-6084

Adam Craig Berger
Principal Investigator

Voorhees

MD Anderson Cancer Center at Cooper-Voorhees

Ashish Bharat Patel
Ph: 856-325-6757

Ashish Bharat Patel
Principal Investigator

Westwood

Oncology Hematology and Internal Medicine

Thomas J. Rakowski
Ph: 201-634-5792

Thomas J. Rakowski
Principal Investigator

New York
Brooklyn

Maimonides Medical Center

Bernadine Donahue
Ph: 718-765-2500

Bernadine Donahue
Principal Investigator

Commack

Memorial Sloan Kettering Cancer Center Commack

Karyn Aalami Goodman
Ph: 212-639-7202

Karyn Aalami Goodman
Principal Investigator

Glens Falls

Glens Falls Hospital

John Patrick Stoutenburg
Ph: 518-926-6700

John Patrick Stoutenburg
Principal Investigator

New York

Laura and Issac Perlmutter Cancer Center at NYU Langone

Silvia Chiara Formenti
Ph: 212-263-4434
Email: prmc.coordinator@nyumc.org

Silvia Chiara Formenti
Principal Investigator

Memorial Sloan-Kettering Cancer Center

Karyn Aalami Goodman
Ph: 212-639-7202

Karyn Aalami Goodman
Principal Investigator

Rochester

Highland Hospital

Yuhchyau Chen
Ph: 585-275-5830

Yuhchyau Chen
Principal Investigator

University of Rochester

Yuhchyau Chen
Ph: 585-275-5830

Yuhchyau Chen
Principal Investigator

Rockville Centre

Memorial Sloan-Kettering Cancer Center Rockville Centre

Karyn Aalami Goodman
Ph: 212-639-7202

Karyn Aalami Goodman
Principal Investigator

Sleepy Hollow

Memorial Sloan-Kettering Cancer Center Sleepy Hollow

Karyn Aalami Goodman
Ph: 212-639-7202

Karyn Aalami Goodman
Principal Investigator

West Harrison

Memorial Sloan-Kettering Cancer Center West Harrison

Karyn Aalami Goodman
Ph: 212-639-7202

Karyn Aalami Goodman
Principal Investigator

North Carolina
Greenville

East Carolina University

Clinton H. Leinweber
Ph: 252-744-2391

Clinton H. Leinweber
Principal Investigator

Kinston

Kinston Medical Specialists PA

Peter Robins Watson
Ph: 252-559-2200

Peter Robins Watson
Principal Investigator

Matthews

Matthews Radiation Oncology Center

Justin Peter Favaro
Ph: 704-384-5369

Justin Peter Favaro
Principal Investigator

Raleigh

Rex Cancer Center

Justin Ja-Li Wu
Ph: 919-784-7209

Justin Ja-Li Wu
Principal Investigator

Ohio
Akron

Akron General Medical Center

Mitchel L. Fromm
Ph: 330-344-6348

Mitchel L. Fromm
Principal Investigator

Summa Akron City Hospital/Cooper Cancer Center

Charles Andrew Kunos
Ph: 330-375-6101

Charles Andrew Kunos
Principal Investigator

Barberton

Summa Barberton Hospital

Charles Andrew Kunos
Ph: 330-375-6101

Charles Andrew Kunos
Principal Investigator

Cincinnati

Bethesda North Hospital

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Good Samaritan Hospital - Cincinnati

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Cleveland

Cleveland Clinic Cancer Center/Fairview Hospital

Andrew D. Vassil
Ph: 866-223-8100

Andrew D. Vassil
Principal Investigator

Cleveland Clinic Foundation

Andrew D. Vassil
Ph: 866-223-8100

Andrew D. Vassil
Principal Investigator

MetroHealth Medical Center

Bruce J. Averbook
Ph: 216-778-8526
Email: kbauchens@metrohealth.org

Bruce J. Averbook
Principal Investigator

Columbus

Grant Medical Center

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Riverside Methodist Hospital

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

The Mark H Zangmeister Center

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Independence

Cleveland Clinic Cancer Center Independence

Andrew D. Vassil
Ph: 866-223-8100

Andrew D. Vassil
Principal Investigator

Maumee

Toledo Clinic Cancer Centers-Maumee

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

Mayfield Heights

Hillcrest Hospital Cancer Center

Andrew D. Vassil
Ph: 866-223-8100

Andrew D. Vassil
Principal Investigator

Medina

Summa Health Center at Lake Medina

Charles Andrew Kunos
Ph: 330-375-6101

Charles Andrew Kunos
Principal Investigator

Ravenna

Robinson Radiation Oncology

Mitchel L. Fromm
Ph: 330-344-6348

Mitchel L. Fromm
Principal Investigator

Sandusky

North Coast Cancer Care

Andrew D. Vassil
Ph: 866-223-8100

Andrew D. Vassil
Principal Investigator

Strongsville

Cleveland Clinic Cancer Center Strongsville

Andrew D. Vassil
Ph: 866-223-8100

Andrew D. Vassil
Principal Investigator

Sylvania

Flower Hospital

Jeffrey Henry Muler
Ph: 419-824-1842

Jeffrey Henry Muler
Principal Investigator

Wooster

Cleveland Clinic Wooster Specialty Center

Andrew D. Vassil
Ph: 866-223-8100

Andrew D. Vassil
Principal Investigator

Oklahoma
Oklahoma City

University of Oklahoma Health Sciences Center

Terence S. Herman
Ph: 405-271-4272
Email: julie-traylor@ouhsc.edu

Terence S. Herman
Principal Investigator

Oregon
Clackamas

Clackamas Radiation Oncology Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Gresham

Legacy Mount Hood Medical Center

Andrew Y. Kee
Ph: 507-538-7623

Andrew Y. Kee
Principal Investigator

Portland

Legacy Good Samaritan Hospital and Medical Center

Andrew Y. Kee
Ph: 507-538-7623

Andrew Y. Kee
Principal Investigator

Providence Portland Medical Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Providence Saint Vincent Medical Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Pennsylvania
Abington

Abington Memorial Hospital

Wayne H. Pinover
Ph: 215-481-2402

Wayne H. Pinover
Principal Investigator

Bryn Mawr

Bryn Mawr Hospital

Albert S. DeNittis
Ph: 866-225-5654

Albert S. DeNittis
Principal Investigator

Danville

Geisinger Medical Center

Thomas James Gergel
Ph: 570-271-5251

Thomas James Gergel
Principal Investigator

Drexel Hill

Delaware County Memorial Hospital

Rachelle M. Lanciano
Ph: 610-284-8237
Email: jolene.garney@crozer.org

Rachelle M. Lanciano
Principal Investigator

Dunmore

Northeast Radiation Oncology Center

Adam Craig Berger
Ph: 215-955-6084

Adam Craig Berger
Principal Investigator

Easton

Easton Hospital

Sonyo Shin
Ph: 610-250-4000

Sonyo Shin
Principal Investigator

Gettysburg

Adams Cancer Center

Amit B. Shah
Ph: 877-441-7957

Amit B. Shah
Principal Investigator

Hanover

Cherry Tree Cancer Center

Amit B. Shah
Ph: 877-441-7957

Amit B. Shah
Principal Investigator

Media

Riddle Memorial Hospital

Albert S. DeNittis
Ph: 866-225-5654

Albert S. DeNittis
Principal Investigator

Paoli

Paoli Memorial Hospital

Albert S. DeNittis
Ph: 866-225-5654

Albert S. DeNittis
Principal Investigator

Philadelphia

Aria Health-Torresdale Campus

Adam Craig Berger
Ph: 215-955-6084

Adam Craig Berger
Principal Investigator

Thomas Jefferson University Hospital

Adam Craig Berger
Ph: 215-955-6084

Adam Craig Berger
Principal Investigator

Sayre

Guthrie Medical Group PC-Robert Packer Hospital

Bradley Walter Lash
Ph: 800-836-0388

Bradley Walter Lash
Principal Investigator

West Reading

Reading Hospital

Albert Yuen
Ph: 610-988-9323

Albert Yuen
Principal Investigator

Wilkes-Barre

Geisinger Wyoming Valley/Henry Cancer Center

Thomas James Gergel
Ph: 570-271-5251

Thomas James Gergel
Principal Investigator

Wynnewood

Lankenau Medical Center

Albert S. DeNittis
Ph: 866-225-5654

Albert S. DeNittis
Principal Investigator

York

WellSpan Health-York Hospital

Amit B. Shah
Ph: 877-441-7957

Amit B. Shah
Principal Investigator

Rhode Island
Providence

Rhode Island Hospital

Howard Safran
Ph: 401-444-1488

Howard Safran
Principal Investigator

South Carolina
Anderson

AnMed Health Cancer Center

Patricia C. Griffin
Ph: 800-486-5941

Patricia C. Griffin
Principal Investigator

Charleston

Medical University of South Carolina

David T. Marshall
Ph: 843-792-9321

David T. Marshall
Principal Investigator

Greenville

Greenville Health System Cancer Institute-Eastside

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Greenville Health System Cancer Institute-Faris

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Greer

Gibbs Cancer Center-Pelham

Patricia C. Griffin
Ph: 800-486-5941

Patricia C. Griffin
Principal Investigator

Greenville Health System Cancer Institute-Greer

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Seneca

Greenville Health System Cancer Institute-Seneca

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Spartanburg

Greenville Health System Cancer Institute-Spartanburg

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Spartanburg Medical Center

Patricia C. Griffin
Ph: 800-486-5941

Patricia C. Griffin
Principal Investigator

South Dakota
Rapid City

Rapid City Regional Hospital

Michael J. Swartz
Ph: 605-716-3982
Email: research@rcrh.org

Michael J. Swartz
Principal Investigator

Tennessee
Nashville

Vanderbilt University/Ingram Cancer Center

Anuradha Bapsi Chakravarthy
Ph: 800-811-8480

Anuradha Bapsi Chakravarthy
Principal Investigator

Texas
Arlington

Texas Oncology-Arlington South

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Austin

Texas Oncology - Central Austin Cancer Center

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Texas Oncology - South Austin Cancer Center

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Texas Oncology-Austin Midtown

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Bedford

Texas Oncology Bedford

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Galveston

University of Texas Medical Branch

Todd Allen Swanson
Ph: 409-772-1950
Email: clinical.research@utmb.edu

Todd Allen Swanson
Principal Investigator

Houston

Memorial Hermann Memorial City Medical Center

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

League City

UTMB Cancer Center at Victory Lakes

Todd Allen Swanson
Ph: 409-772-1950
Email: clinical.research@utmb.edu

Todd Allen Swanson
Principal Investigator

Longview

Texas Oncology-Longview Cancer Center

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Round Rock

Texas Oncology - Round Rock Cancer Center

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Texas Oncology-Seton Williamson

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Sherman

Texas Cancer Center-Sherman

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Sugar Land

Texas Oncology Cancer Center Sugar Land

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Tyler

Tyler Cancer Center

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Utah
American Fork

American Fork Hospital / Huntsman Intermountain Cancer Center

R. Jeffrey Lee
Ph: 801-507-3950

R. Jeffrey Lee
Principal Investigator

Logan

Logan Regional Hospital

R. Jeffrey Lee
Ph: 801-507-3950

R. Jeffrey Lee
Principal Investigator

Murray

Intermountain Medical Center

R. Jeffrey Lee
Ph: 801-507-3950

R. Jeffrey Lee
Principal Investigator

Ogden

McKay-Dee Hospital Center

R. Jeffrey Lee
Ph: 801-507-3950

R. Jeffrey Lee
Principal Investigator

Provo

Utah Valley Regional Medical Center

R. Jeffrey Lee
Ph: 801-507-3950

R. Jeffrey Lee
Principal Investigator

Saint George

Dixie Medical Center Regional Cancer Center

R. Jeffrey Lee
Ph: 801-507-3950

R. Jeffrey Lee
Principal Investigator

Salt Lake City

Huntsman Cancer Institute/University of Utah

Jonathan D. Tward
Ph: 801-581-4477
Email: clinical.trials@hci.utah.edu

Jonathan D. Tward
Principal Investigator

Utah Cancer Specialists-Salt Lake City

R. Jeffrey Lee
Ph: 801-507-3950

R. Jeffrey Lee
Principal Investigator

Virginia
Hampton

Sentara Cancer Institute at Sentara CarePlex Hospital

Scott S. Williams
Ph: 757-388-2406

Scott S. Williams
Principal Investigator

Norfolk

Sentara Hospitals

Scott S. Williams
Ph: 757-388-2406

Scott S. Williams
Principal Investigator

Virginia Beach

Sentara Virginia Beach General Hospital

Scott S. Williams
Ph: 757-388-2406

Scott S. Williams
Principal Investigator

Washington
Gig Harbor

Tacoma/Valley Radiation Oncology Centers-Gig Harbor

John A. Keech
Ph: 907-458-5380

John A. Keech
Principal Investigator

Longview

Saint John Medical Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Puyallup

Tacoma/Valley Radiation Oncology Centers-Puyallup

John A. Keech
Ph: 907-458-5380

John A. Keech
Principal Investigator

Tacoma

Multicare Health System

John A. Keech
Ph: 907-458-5380

John A. Keech
Principal Investigator

Northwest Medical Specialties PLLC

Yoshio Inoue
Ph: 253-403-2394

Yoshio Inoue
Principal Investigator

Tacoma/Valley Radiation Oncology Centers-Saint Joe's

John A. Keech
Ph: 907-458-5380

John A. Keech
Principal Investigator

Vancouver

Legacy Salmon Creek Hospital

Andrew Y. Kee
Ph: 507-538-7623

Andrew Y. Kee
Principal Investigator

PeaceHealth Southwest Medical Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

West Virginia
Charleston

West Virginia University Charleston

Steven James Jubelirer
Ph: 304-344-3457

Steven James Jubelirer
Principal Investigator

Morgantown

West Virginia University Healthcare

Malcolm David Mattes
Ph: 304-293-2745
Email: sfilburn@hsc.wvu.edu

Malcolm David Mattes
Principal Investigator

Wheeling

Wheeling Hospital/Schiffler Cancer Center

Jondavid Pollock
Ph: 304-243-6442

Jondavid Pollock
Principal Investigator

Wisconsin
Green Bay

Saint Mary's Hospital

James L. Leenstra
Ph: 920-433-8889

James L. Leenstra
Principal Investigator

Saint Vincent Hospital

James L. Leenstra
Ph: 920-433-8889

James L. Leenstra
Principal Investigator

La Crosse

Gundersen Lutheran Medical Center

Kurt Oettel
Ph: 608-775-2385
Email: cancerctr@gundluth.org

Kurt Oettel
Principal Investigator

Marinette

Bay Area Medical Center

James L. Leenstra
Ph: 920-433-8889

James L. Leenstra
Principal Investigator

Milwaukee

Froedtert and the Medical College of Wisconsin

Beth A. Erickson
Ph: 414-805-4380

Beth A. Erickson
Principal Investigator

Sturgeon Bay

Door County Cancer Center

James L. Leenstra
Ph: 920-433-8889

James L. Leenstra
Principal Investigator

Canada

Ontario
London

London Regional Cancer Program

Barbara J. Fisher
Ph: 519-685-8600

Barbara J. Fisher
Principal Investigator

Ottawa

Ottawa Hospital and Cancer Center-General Campus

Jason Rene Pantarotto
Ph: 613-761-4395
Email: info@ohri.ca

Jason Rene Pantarotto
Principal Investigator

Israel

Petach Tikva

Rabin Medical Center

Salomon M. Stemmer
Ph: 888-823-5923
Email: ctsucontact@westat.com

Salomon M. Stemmer
Principal Investigator

Tel Aviv

Tel Aviv Sourasky Medical Center

Ravit Geva
Ph: 011-972-3-6974761
Email: mop@tasmc.health.gov.il

Ravit Geva
Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01013649

Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the ClinicalTrials.gov record via the link above for more information about participating sites.